Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study evaluated orforglipron, an investigational, once-daily oral small molecule ...

Scientists are discovering that the oral microbiome—home to hundreds of species of bacteria and fungi—may help predict ...

Compared to Sotyktu (deucravacitinib), which was approved by the FDA for plaque psoriasis in 2022 and brought in sales of ...

Eli Lilly's oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...

GURU Shyam Jamalabad, a dentist with over four decades of experience, offers practical advice about how to keep your teeth ...

If approved, zasocitinib would stand out as one of the first drugs discovered with the help of artificial intelligence.

Takeda reported positive topline results from two pivotal Phase 3 trials of zasocitinib (TAK-279), a once-daily, highly selective oral TYK2 inhibitor, in adults with moderate-to-severe plaque ...

Johnson & Johnson's portfolio reshaping should enhance margins and long-term growth prospects. Click here to read why JNJ ...

London Borough of Bromley, England – November 18, 2025 – PRESSADVANTAGE – Smile 4 U – Bromley has announced the availability ...

Immunome (IMNM) surges after positive phase 3 results for varegacestat in desmoid tumors. Read the latest analysis on the ...

The FDA has cleared the initiation of a pivotal Phase 3 trial testing pridopidine in people with early, rapidly progressive ...

ENV-308 is a first-in-class, once-daily oral therapy designed for chronic weight management, emphasizing high-quality weight loss with muscle mass preservation and durable long-term maintenancePhase 1 ...